|
Exclusivity Start Date |
Generic Name |
Trade Name |
Indication for Original Approval |
|
1/18/96 |
Respiratory syncytial virus immune globulin (human) |
Respigam |
Prophylaxis of respiratory syncytial virus (RSV) lower respiratory tract infections in infants and young children at high risk of RSV disease |
|
9/26/97 |
Sermorelin acetate |
Geref |
Treatment of idiopathic or organic growth hormone deficiency in children with growth failure |
|
5/27/99 |
Etanercept |
Enbrel |
Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying antirheumatic drugs |
|
9/21/99 |
Caffeine |
Cafcit |
Short-term treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age |
|
6/20/00 |
Somatropin (r-DNA) |
Genotropin |
Long-term treatment of pediatric patients who have growth failure due to Prader-Willi syndrome (PWS) |
|
7/12/02 |
Rasburicase |
Elitek |
Treatment of malignancy-associated or chemotherapy-induced hyperuricemia |
|
7/29/03 |
Ribavirin |
Rebetol |
Treatment of chronic hepatitis C among previously untreated pediatric patients at least 3 years of age or older |
|
10/23/03 |
Botulism immune globulin |
Babybig |
Indicated for treatment of infant botulism caused by type A or type B Clostridium botulinum |
|
12/28/04 |
Clofarabine |
Clolar |
Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens |
|
8/11/05 |
Meloxicam |
Mobic |
For relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients 2 years of age or older |
|
8/30/05 |
Mecasermin |
Increlex |
Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH |
|
12/12/05 |
Mecasermin rinfabate |
Iplex |
Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH |